Início/ABT

Public research page

Market data comes from the live feed. The company research below uses verified public sources, but it is not a real-time personalized AI conclusion.

Analyze ABT in workspace
ABTNYSE/health care

Abbott Laboratories

$92.11Down-1,82 (-1,94%)
Research reviewed: 12 de jul. de 2026, 00:00 UTC
Research overview3-month price contextInvestment thesisKey catalystsLatest earnings researchRecent newsData and research sources

Research overview

Abbott Laboratories operates in Health Care Equipment within the health care sector. This profile tracks its company-specific earnings drivers, valuation conditions, and primary-source risks.

Открытие
93,95
Максимум
94,00
Минимум
91,64
Капитализация
160,44 млрд
P/E
25.80
Максимум за 52 недели
--
Дивиденд
2.680%
Квартальный дивиденд
--

3-month price context

O gráfico mostra a tendência recente de 3 meses para ajudar usuários a entender a estrutura de curto prazo antes de abrir o workspace completo de pesquisa.

Investment thesis

Base case
Broad growth across Abbott's medical-device portfolio, including diabetes care and structural heart, can remain the company's primary organic growth engine. The base case remains conditional on nutrition weakness staying manageable.
Bull case
Broad growth across Abbott's medical-device portfolio, including diabetes care and structural heart, can remain the company's primary organic growth engine. The Exact Sciences acquisition establishes a meaningful oncology-diagnostics platform and adds long-term growth opportunities in cancer screening and precision diagnostics. Continued growth in key emerging markets can provide a diversified contribution from established branded generics.
Bear case
Nutrition sales declined in the quarter, and persistent weakness could offset strength in medical devices and established pharmaceuticals. The large Exact Sciences transaction introduces integration, financing, dilution, and execution risks before projected strategic benefits are realized. Ongoing preterm infant formula litigation creates uncertain legal costs and potential reputational pressure for the nutrition business.
Thesis invalidation
Reassess the thesis if nutrition sales declined in the quarter, and persistent weakness could offset strength in medical devices and established pharmaceuticals.

Key catalysts

  • Medical devices growth

    Broad growth across Abbott's medical-device portfolio, including diabetes care and structural heart, can remain the company's primary organic growth engine.

  • Oncology diagnostics expansion

    The Exact Sciences acquisition establishes a meaningful oncology-diagnostics platform and adds long-term growth opportunities in cancer screening and precision diagnostics.

  • Established pharmaceuticals growth

    Continued growth in key emerging markets can provide a diversified contribution from established branded generics.

Principal risks

  • Nutrition weakness

    Nutrition sales declined in the quarter, and persistent weakness could offset strength in medical devices and established pharmaceuticals.

  • Exact Sciences integration

    The large Exact Sciences transaction introduces integration, financing, dilution, and execution risks before projected strategic benefits are realized.

  • Infant-formula litigation

    Ongoing preterm infant formula litigation creates uncertain legal costs and potential reputational pressure for the nutrition business.

Latest earnings research

2026 Q1

For the quarter ended March 31, 2026, Abbott reported sales growth led by medical devices, established pharmaceuticals, and diagnostics, while nutrition declined; management updated its full-year outlook to include the completed Exact Sciences acquisition.

Valuation interpretation

  • Sustained medical-device growth and successful oncology-diagnostics expansion can support a diversified health-care quality premium.
  • Nutrition weakness and the scale of Exact Sciences integration warrant a discount until acquired growth and financial synergies become visible.

Peer research

BSXISRGSYK

Recent news

24/7 Wall St. · 5 часов назад

Abbott Labs Vs. Pfizer: Which Discounted Healthcare Titan Screens as the Bigger Value Trap?

Zacks · 13 часов назад

Unlocking Q2 Potential of Abbott (ABT): Exploring Wall Street Estimates for Key Metrics

MedTech Dive · 15 часов назад

Freenome colorectal cancer test data improve on earlier results

Insider Monkey · 17 часов назад

Baird Initiates Coverage on Abbott Laboratories (ABT) Stock with Outperform Rating

Simply Wall St. · позавчера

Does Libre 3 Plus Integration Expand Tandem’s Interoperability Edge And Bull Case For TNDM?

Motley Fool · позавчера

AbbVie Is Already a Dividend King. Here's Why the $10.9 Billion Apogee Deal Could Make It a Dynasty

Data and research sources

Research updated: 12 de jul. de 2026, 00:00 UTC
3 verified sources
Abbott Reports First-Quarter 2026 Results; Updates Guidance to Reflect Acquisition of Exact SciencesAbbott Laboratories · earningsVerified

Fetched: 12/07/2026, 0:00:00 UTC

Published: 16/04/2026, 00:00:00

Open original source
Abbott Investor RelationsAbbott Laboratories · companyVerified

Fetched: 12/07/2026, 0:00:00 UTC

Open original source
Abbott Form 10-Q for the Quarter Ended March 31, 2026U.S. Securities and Exchange Commission · filingVerified

Fetched: 12/07/2026, 0:00:00 UTC

Open original source

Continue in the research workspace

Keep ABT in context, run a multi-agent analysis, and monitor thesis changes.

Analyze ABT free

Conheça todo o sistema de análise

Cada etapa tem uma função clara e deixa um resultado auditável.

Metodologia de análiseLer relatórios de mercadoExplorar ações

Continue researching this stock

Analista de Mercado

Analista de Mercado se especializa na etapa de Observar dentro de Pesquisa central e organiza o contexto para os próximos papéis.

Analista Fundamentalista

Analista Fundamentalista se especializa na etapa de Observar dentro de Pesquisa central e organiza o contexto para os próximos papéis.

Analista de Notícias

Analista de Notícias se especializa na etapa de Observar dentro de Pesquisa central e organiza o contexto para os próximos papéis.

Gestor de Risco

Gestor de Risco se especializa na etapa de Monitorar dentro de Risco e monitoramento e organiza o contexto para os próximos papéis.